Alexander T. Young, Ph.D.
Professorial Fellow
Contact(s): atyoung@up.edu.ph
Educ. Background:
Ph.D. Medical Sciences, Harvard University, USA (1987-1991)
A.M. Virology, Harvard University, USA (1984-1986)
B.A. Biochemistry, Cornell University (1980)
Professional:
Research Professor, Philippine Genome Center (2018-2019)
CEO Mirabila Marine, USA (2011-2018)
CEO Mirabila, USA (1998-2018)
CEO United Genetics, USA (1991-1995)
Merck, USA (1982-1984)
Cetus Corporation, USA (1980-1981)
Head: Genomics Effects on Nature by Environmental Stressors

Interests / ProjectsCourses Handled & Other InformationPublication

Interests:

Dr. Alexander Young is the newest faculty member of the Institute of Environmental Science & Meteorology. Dr. Young is an American citizen that came to the Philippines because the Philippines is the number one place in the world to study marine biodiversity. Dr. Young is the University of the Philippines’ first Professorial fellow, a position especially created to allow foreigners to hold a faculty position and conduct fulltime research at the University of the Philippines. Originally trained in the biomedical Sciences with experience in Human Genome Project, the biotechnology industry and biotechnology venture capital. Dr. Young now wants to use his experience in the study of human diseases (to help save people) towards the study of marine diseases caused by environmental pollutants (to help save the planet).

Dr. Young integrates field studies with advanced high-throughput laboratory and computational technologies to study mechanisms of coral bleaching by anthropogenic stressors, mechanisms of symbiosis of coral reef organisms with zooxanthellae, and the development of molecular diagnostics to protect coral reefs.

Research Projects:

  • Geospatial GPS mapping of bleached and unbleached coral reef organisms in Puerto Princesa Bay, Palawan to identify field-validated, stress-specific biomarkers of coral bleaching
  • Genomic transcriptomic, proteomic, and metabolic profiling of a model organism for coral bleaching exposed to anthropogenic stressors
  • Application of bioinformatics to genomic, transcriptomic, proteomic, and metabolimic studies of coral bleaching to identify stress-specific biomarkers
  • Mechanisms of symbiosis between coral reef organisms and Symbiodinium
  • Profiling of microplastic pollution in Manila Bay from the Pasig River
  • Microplastic effects on coral reef organisms

Courses:

  • Env Sci 228 Environmental Biotechnology
  • Env Sci 297 Special topics in Environmental Science
  • Env Sci 300 Masteral thesis
  • Env Sci 399 doctoral dissertation

Other relevant information:

Professor Young spent half his career in biotechnology venture capital and biotechnology business development before returning to academia through the University of the Philippines. Here are some of Dr. Young’s activities in the past:

  • Dr. Young led healthcare and biotechnology venture capital investments ranging from a 4 million Euro investment in a startup biotechnology company (founded by a Nobel Laureate and later sold to Amgen for US $300 million)  to leading a US $32 million investment in a genomic diagnostics company
  • Dr. Young developed the scientific strategy for a US $465 million (PHP 25 billion) genomics-based drug discovery alliance between a German pharmaceutical company and a US genomics company. This was then the largest corporate partnership in the history of biotechnology and voted one of the top ten deals that changed biotechnology.
  • Professor Young was the invited chairman for five international conferences of 500 people held in the USA for functional genomics, bioinformatics, strategic alliances, and drug discovery
  • Dr. Young founded a gene therapy company
  • Young helped sequence the first genome of a human virus while at Cornell, sequenced one of the first regulatory regions of a eukaryotic gene while at Cornell, cloned several genes for human alpha-interferons while at Cetus Corporation, cloned hepatitis A virus while at Merck, and helped decipher how aberrant signal transduction pathways causes cancer while at Harvard, including the first demonstration that tyrosine phosphorylation induces protein-protein interaction.

RECENT PUBLICATION:

    • Young AT (2019) Creating a roadmap for building a sustainable genomics facility in the Philippines Philippine Journal of Science 148 (S1): 15-32
    • Briones YL, MR Castro, RD Jalandoni, HN Adorna, JA Dizon and AT Young (2019 in press) A directed minimum connected dominating set for protein-protein interaction networks Theory and Practice of Computation, Proceedings of the Workshop on Computation: Theory and Practice (WCTP 2019) September 26 – 27, 2019 Manila, The Philippines (London, CRC Press)
    • Young AT et al (in preparation) High resolution geospatial mapping of clownfish-hosting sea anemones associates bleaching with petroleum hydrocarbon BTEX: Bioinformatic prediction of potential petroleum hydrocarbon stress-specific molecular biomarkers
    • Young AT (2018) Applying technologies from the biomedical industry to marine biology (Abstract only and talk) 3rd International Conference on West Philippine Sea (Puerto Princesa) May 3, 2018
    • Young AT and L Creencia (2014) High resolution geospatial mapping of bleached sea anemones (Heteractis) and correlation to anthropogenic stress from sedimentation, farming, and petroleum hydrocarbons (Abstract only and talk) 1st International Conference on West Philippine Sea (Puerto Princesa) February 21, 2014
    • Young A (2011) Pursuing next-generation therapeutic antibodies as the next source of blockbuster drugs Spectrum, Discovery and Innovation: Technologies, Strategies, and Dealmaking, Decision Resources June 2011
    • Young A and BM Bolten (2009) Riding the biotech economic tsunami—Surfing to safety or wipeout? Spectrum, Drug Discovery and Design, Decision Resources May 2009 4: 1-35
    • Young A (2009) Insights into platform technology and early-stage pipeline mergers and acquisitions Spectrum, Drug Discovery and Design, Decision Resources March 30, 2009 2: 1-22
    • Young A and BM Bolten (2008) Fueling the drug discovery engine: Biotech investment and business trends Spectrum, Drug Discovery and Design, Decision Resources June 2008 5: 1-48
    • Young A (2007) Challenges for a maturing biotechnology industry: Evolve or perish Spectrum Pharmaceutical Industry Dynamics, Decision Resources August 2007 10: 1-22
    • Young A and B Bolten (2007) Pharma antes up: Investment and business trends driving biotechnology (2006) Spectrum Pharmaceutical Industry Dynamics, Decision Resources June 2007 5: 1-26
    • Young A (2006) Translational medicine: Assessing the feasibility and challenges review Spectrum, Drug Discovery and Design, Decision Resources September 2006 7: 1-20
    • Young A (2006) Who’s buying what in biotech? Investment and business trends driving biotechnology Spectrum, Drug Discovery and Design, Decision Resources April 2006 3: 1-23
    • Young A and B Bolten (2005) Investment and business trends in biotechnology: 2004 in review Spectrum, Drug Discovery and Design, Decision Resources March 2005 2: 1-18
    • Young A (2005) Obesity and drug discovery: Success and challenges for a new pharmaceutical market Spectrum, Drug Discovery and Design, Decision Resources June 2005 4: 1-19
    • Young A (2004) Biodefense opportunities in the biotechnology and pharmaceutical industries Spectrum, Drug Discovery and Design, Decision Resources July 2004 6: 1-21
    • Young A and B Bolten (2004) Corporate investment and business trends in biotechnology: 2003 in review Spectrum, Drug Discovery and Design, Decision Resources April 2004 3: 1-24
    • Young A and B Bolten (2003) Corporate investment and business trends in biotechnology: 2002 in review Spectrum, Drug Discovery and Design, Decision Resources March 2003 3: 1-18
    • Young A and B Bolten (2002) Corporate investment and business trends in biotechnology: 2001 in review Spectrum, Drug Discovery and Design, Decision Resources March 2002 2: 1-18
    • Young A (1999) The race to create and capture value from genomics Spectrum, Drug Discovery and Design Decision Resources October 1999
    • Young A (1999) Current and future trends in drug discovery Chapter 4 pp89-104 (eds. Haberman AB, GR Lenz and D Vaccaro) (Decision Resources, Waltham, MA)
    • Young A and A Regalado (1998) Proteomics: Emergence of a new technology for drug discovery and development Spectrum Drug Discovery and Design March 26, 1999
    • Young AT, J Dahl, Hausdorff SF, Bauer P, MJ Birnbaum and TL Benjamin (1995) Phosphatidylinositol 3-kinase binding to polyoma virus middle tumor antigen mediates elevation of glucose transport by increasing translocation of the GLUT1 transporter Proc Natl Acad Sci USA 92: 11613-11617 Impact Factor 10.4
    • Young AT (1993) Gene therapy using targeted viral vectors Patent Cooperation Treaty, World Intellectual Property Organization
    • Talmage D, R Freund, AT Young, J Dahl, C Dawe, and TL Benjamin (1989) Phosphorylation of middle T by pp60csrc: A switch for binding of phosphatidylinositol 3-kinase and optimal tumorigenesis Cell 59: 55-65 Impact Factor 31
    • Lips DL, PW Majerus, FR Gorga, AT Young and TL Benjamin (1989) Phosphatidylinositol 3phosphate is present in normal and transformed fibroblasts and is resistant to hydrolysis by bovine brain phospholipase C II J Biol Chem 264: 8759-8763 Impact Factor 4
    • Young AT, D Talmage, R Freund, C Dawe and TL Benjamin (1988) Phosphorylation of polyoma virus middle T on tyrosine 315 is required for efficient tumor induction and for association with type I phosphatidylinositol kinase activity (Abstract) Cold Spring Harbor Meeting on SV40, Polyoma, and Adenoviruses
    • Linemeyer DL, JG Menke, A Martin-Gallardo, JV Hughes, AT Young and SW Mitra (1985) Molecular cloning and partial sequencing of hepatitis A viral cDNA J Virology 54: 247- 255 Impact Factor 5
    • Stiles JI, JW Szostak, AT Young, R Wu, S Consaul and F Sherman (1981) DNA sequence of a mutation in the leader region of the yeast iso-1-cytochrome c mRNA Cell 25: 277-284  Impact Factor 31
    • Yang RCA, AT Young, and R Wu (1981) BK virus DNA sequence coding for the t and T antigens and evaluation of methods for determining sequence homology J Virology 34: 416-430 Impact Factor 5